Table 4: Pre-operative spinal opioid versus control (spinal LA anaesthesia in both groups)

Table 4: Pre-operative spinal opioid versus control (spinal LA anaesthesia in both groups): study details and qualitative outcomes




























































Study


n treatment/


control


Comparison


Supplemental


analgesic


VAS scores and type of pain, where specified


Time to first analgesic request


Use of supplemental analgesic


Other important outcomes


Cole 2000


(LoE 1)


 


17/18


On a background of spinal bupivacaine anaesthesia: spinal morphine (0.3 mg; 1 mg/ml) (Op) vs. saline (Cont)


Postop: oral or rectal diclofenac (50 mg every 8 h); PCA-morphine, IV


VAS on movement: Op superior at all time points recorded: 4 h (p<0.01), 12 h (p=0.01) and 24 h (p<0.05)


__


PCA morphine: Op superior during  the 1st 24 h postop (p<0.01)


Pain


Number of patients reporting absent/mild pain: NS; patient satisfaction with analgesia: NS


PONV


Treated emesis: NS


Respiratory function


Respiratory distress indices: NS; median SpO2 (%): Op<Cont (p<0.05)


Complications


Pruritus, mild/moderate hypoxaemia: NS


Fernandez-Galinski 1996


(LoE 1)


 


19/21


On a background of spinal bupivacaine anaesthesia: fentanyl (25 µg) (Op) vs. hyperbaric bupivacaine (12.5 mg) alone (Cont)


Postop: used, but no details given


VAS at time of first analgesic request: Op superior (p<0.001) (knee group)


N/A (knee and hip combined)


__


Pain


Facial expression test scores (1–8): Op superior (p<0.02) (knee group)


PONV


N/A (knee and hip combined)


Complications


N/A (knee and hip combined)


Jacobson 1989


(LoE 1)


7/7/7/7/7


On a background of spinal bupivacaine anaesthesia: 2.5 mg spinal diamorphine (A) vs. 1.5 mg spinal diamorphine (B) vs. 0.75 mg spinal diamorphine (C) vs. 0.25 mg spinal diamorphine (D) vs. 0 mg spinal diamorphine (NT)


Postop: IV morphine until adequate analgesia achieved; IM morphine, as required


NS at 2­–22 h


Time to initial supplemental morphine: A, B, C and D superior (p<0.05, in all cases)


Supplemental morphine: NS


PONV


NS


Complications


Pruritus: NT superior compared with A, B and C (p<0.05, in all cases); urinary retention: NS


 


Sites 2003


(LoE 1)


 


20/21


On a background of spinal bupivacaine anaesthesia: spinal morphine (250 µg) (Op) vs. saline (Cont)


Postop: PCA-morphine IV, as required; IV ketorolac (15–30 mg) every 6 h


Op superior at 1, 2 and 4 h (p<0.01, in all cases) and at 24 h (p<0.05), but not at 6 or 12 h


__


Morphine consumption: Op superior at 2–4 h and 6–12 h (p<0.05, in both cases), but not at other time intervals (i.e. at 0–1 h, 1–2 h, 4–6 h, 12–24 h)


PONV


NS (moderate-to-severe PONV)


Complications


Hypotension, pruritus, oxygen desaturations: NS


Tan 2001


(LoE 1)


 


20/20


On a background of spinal bupivacaine anaesthesia: spinal morphine 300 µg (Op) vs. 0.5 ml saline (Cont)


Postop: IM diclofenac (75 mg) if VAS>4 and every 12 h, as required


Op superior at 8 h (p<0.05); overall 24 h pain score: Op superior (p<0.05)


Duration of spinal analgesia: Op superior (p<0.05); time to first diclofenac request: Op superior (p<0.05)


Number of IM diclofenac doses: NS


PONV


Nausea/vomiting: NS


Complications


Pruritus: Cont superior (p<0.05); dizziness: NS